Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 307

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition

Open access
Gao, Dingcheng, Joshi, Natasha, Choi, Hyejin, Ryu, Seongho, Hahn, Mary, Catena, Raul, Sadik, Helen, Argani, Pedram, Wagner, Patrick, Vahdat, Linda T., Port, Jeffrey L., Stiles, Brendon, Sukumar, Saraswati, Altorki, Nasser K., Rafii, Shahin, Mittal, Vivek·2012·Cancer Research

Abstract

Tumors systemically initiate metastatic niches in distant target metastatic organs. These niches, composed of bone marrow–derived hematopoietic cells, provide permissive conditions for future metastases. However, the mechanisms by which these cells mediate outgrowth of metastatic tumor cells are not completely known. Using mouse models of spontaneous breast cancer, we show enhanced recruitment of bone marrow–derived CD11b+Gr1+ myeloid progenitor cells in the premetastatic lungs. Gene expression profiling revealed that the myeloid cells from metastatic lungs express versican, an extracellular matrix proteoglycan. Notably, versican in metastatic lungs was mainly contributed by the CD11b+Ly6Chigh monocytic fraction of the myeloid cells and not the tumor cells or other stromal cells. Versican knockdown in the bone marrow significantly impaired lung metastases in vivo, without impacting their recruitment to the lungs or altering the immune microenvironment. Versican stimulated mesenchymal to epithelial transition of metastatic tumor cells by attenuating phospho-Smad2 levels, which resulted in elevated cell proliferation and accelerated metastases. Analysis of clinical specimens showed elevated versican expression within the metastatic lung of patients with breast cancer. Together, our findings suggest that selectively targeting tumor-elicited myeloid cells or versican represents a potential therapeutic strategy for combating metastatic disease. Cancer Res; 72(6); 1384–94. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-2905

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 307

Metadata

Authors
Gao, D., Joshi, N., Choi, H., Ryu, S., Hahn, M., Catena, R., Sadik, H., Argani, P., Wagner, P., Vahdat, L. T., Port, J. L., Stiles, B., Sukumar, S., Altorki, N. K., Rafii, S., & Mittal, V.
Venue
Cancer Research
Published
2012-03-14
Volume
72
Issue
6
Pages
1384-1394
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2065678781
Cited by
307
References
9
FWCI
9.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-2905
The paper
Gao, D., Joshi, N., Choi, H., Ryu, S., Hahn, M., Catena, R., Sadik, H., Argani, P., Wagner, P., Vahdat, L. T., Port, J. L., Stiles, B., Sukumar, S., Altorki, N. K., Rafii, S., & Mittal, V. (2012). Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-2905

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.